<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03236857</url>
  </required_header>
  <id_info>
    <org_study_id>M13-833</org_study_id>
    <secondary_id>2017-000439-14</secondary_id>
    <nct_id>NCT03236857</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies</brief_title>
  <official_title>A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech/Roche</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of
      venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended
      Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and
      young adult participants with relapsed or refractory malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2017</start_date>
  <completion_date type="Anticipated">April 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 25, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-24 post-dose of venetoclax</measure>
    <time_frame>Up to approximately 2 weeks</time_frame>
    <description>Area under the plasma concentration-time curve from 0 to 24 hours (AUC24) post-dose of venetoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 dose (RPTD) of venetoclax</measure>
    <time_frame>First 21 days venetoclax monotherapy</time_frame>
    <description>Venetoclax RPTD is the dose determined based on adverse event reporting and dose-limiting toxicity information from all participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Dose limiting toxicities (DLT) of Venetoclax Monotherapy</measure>
    <time_frame>First 21 days venetoclax monotherapy</time_frame>
    <description>A DLT is any Grade 3 or higher non-hematologic adverse event (AE) with exceptions outlined in the protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of venetoclax</measure>
    <time_frame>Up to approximately 2 weeks</time_frame>
    <description>Time to maximum plasma concentration (Tmax) of venetoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of venetoclax</measure>
    <time_frame>Up to approximately 2 weeks</time_frame>
    <description>Maximum plasma concentration (Cmax) of venetoclax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>ORR is defined as the proportion of participants who achieved a response according to established criteria described in detail in the study protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Response (PR) rate</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>PR is defined according to established criteria for each tumor type and is described in detail within the study protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) rate</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>CR is defined according to established criteria for each tumor type and is described in detail within the study protocol.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Relapsed or Refractory Malignancies</condition>
  <condition>Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)</condition>
  <condition>Relapsed or Refractory Acute Myeloid Leukemia (AML)</condition>
  <condition>Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)</condition>
  <condition>Relapsed or Refractory Neuroblastoma</condition>
  <condition>Relapsed or Refractory Tumors That Expresses B Cell Lymphoma 2 (BCL-2)</condition>
  <arm_group>
    <arm_group_label>Venetoclax with or without chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax administered orally once daily (QD) with various doses and dosing regimens with or without chemotherapy at the discretion of the investigator. Allowed chemotherapy regimens as outlined in the study protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>Dexamethasone and/or vincristine and/or pegasparaginase OR cytarabine and/or etoposide and/or pegasparaginase; tyrosine kinase inhibitor; low-dose cytarabine OR azacitidine OR decitabine; rituximab and/or dexamethasone and/or vincristine; cyclophosphamide and/or topotecan</description>
    <arm_group_label>Venetoclax with or without chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venetoclax</intervention_name>
    <description>Tablet for oral suspension (participants who cannot swallow tablets in both Part 1 Dose Determination and Part 2 Cohort Expansion); oral tablet for participants able to swallow tablets (Part 2 Cohort Expansion only)</description>
    <arm_group_label>Venetoclax with or without chemotherapy</arm_group_label>
    <other_name>ABT-199</other_name>
    <other_name>GDC-0199</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have relapsed or refractory cancer.

          -  Participants must have adequate hepatic and kidney function.

          -  Participants less than or equal to 16 years of age must have performance status of
             Lansky greater than or equal to 50% and participants greater than 16 years of age must
             have performance status of Karnofsky greater than 50%.

          -  Participants with solid tumors (with the exception of neuroblastoma) must have
             adequate bone marrow function in Part 1.

          -  For the fifth cohort during Part 2 Cohort Expansion, participants with solid tumors
             must have evidence of BCL-2 expression.

        Exclusion Criteria:

          -  Participants with primary brain tumors or disease metastatic to the brain.

          -  For participants with leukemia, has overt central nervous system (CNS) disease (CNS 3
             status).

          -  Participants who have received any of the following within the listed time frame,
             prior to the first dose of study drug

               -  Biologic agent (i.e., antibodies) for anti-neoplastic intent within 30 days

               -  CAR-T infusion or other cellular therapy within 30 days

               -  Anticancer therapy including blinatumomab or chemotherapy, radiation therapy,
                  targeted small molecule agents, investigational agents within 14 days or 5
                  half-lives, whichever is shorter

               -  Steroid therapy for anti-neoplastic intent within 5 days

               -  Requires ongoing hydroxyurea (hydroxyurea permitted up to first dose)

          -  Participants who are less than 100 days post-transplant, or greater than or equal to
             100 days post-transplant with active graft versus host disease (GVHD), or are
             receiving immunosuppressant therapy within 7 days prior to first dose of study drug.

          -  Participants who are less than 6 weeks post-131 I-metaiodobenzylguanidine (mIBG)
             therapy.

          -  Participants who have received the following within 7 days prior to the first dose of
             study drug:

               -  Strong and moderate Cytochrome P450 3A (CYP3A) inhibitors (Part 1 Dose
                  Determination);

               -  Strong and moderate CYP3A inducers (Part 1 Dose Determination and Part 2 Cohort
                  Expansion).

          -  Participants who have not recovered from clinically significant adverse
             effect(s)/toxicity(s) of the previous therapy.

          -  Participants who have active, uncontrolled infections.

          -  Participants with malabsorption syndrome or any other condition that precludes enteral
             administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-2204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlan</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065-6007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hosp Philadephia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Jude Childrens Res Hosp</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Primary Children's</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3522</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lady Cilento Children's Hospit</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Women and Childrens Hospital</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon CEDEX 08</city>
        <state>Rhone</state>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Robert Debre</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hop Ophtalmique Jules Gonin</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Virchow Klini</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ Hosp Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus MC - Sophia</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prinses Maxima Center</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary, Newc</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2017</study_first_submitted>
  <study_first_submitted_qc>July 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2017</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>Venetoclax</keyword>
  <keyword>pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

